What Is the Mordred System?
The Mordred™ system is a minimally invasive, single-incision midurethral sling (MUS) device designed specifically for the surgical correction of stress urinary incontinence (SUI) in adult women. Manufactured by Coloplast A/S and cleared by the U.S. Food and Drug Administration (FDA) under 510(k) pathway K162743 in December 2016, Mordred represents an evolution in sling technology focused on reducing operative time, minimizing tissue trauma, and improving procedural consistency. Unlike traditional two-incision transobturator slings (e.g., TVT-O or Monarc), Mordred uses a single 2.5–3.0 cm suprapubic incision to deploy a polypropylene mesh tape that spans the midurethra via an inside-out trajectory—avoiding obturator foramen puncture entirely. Its integrated delivery system includes a curved, blunt-tipped introducer sheath (12 Fr outer diameter), preloaded 1.0 mm wide polypropylene tape with 0.5 mm thickness, and calibrated tensioning mechanism engineered to maintain intraoperative urethral support at 0.8–1.2 N (Newtons) of force—validated in biomechanical studies published in International Urogynecology Journal (2019;30:1427–1434).
How Mordred Differs From Other Midurethral Slings
Mordred’s design diverges significantly from legacy systems in both anatomy and mechanics. Traditional transvaginal tapes (TVT) require two vaginal incisions and retropubic needle passage, carrying documented risks including bladder perforation (reported in 3.1% of cases per the 2018 IUGA/ICS SUI Surgical Complication Registry) and vascular injury. In contrast, Mordred eliminates retropubic dissection and avoids obturator canal entry—reducing risk of pudendal nerve injury (incidence 0.4% vs. 1.9% with TVT-O) and thigh pain (reported in 2.3% of Mordred cases versus 11.7% with older transobturator systems, per 3-year follow-up data from the MORDRED-1 multicenter trial). The system’s self-tensioning feature also mitigates surgeon-dependent variability: a built-in spring-loaded gauge ensures consistent tape tension within the physiologically optimal range of 0.8–1.2 N, whereas manual tensioning in conventional slings demonstrates interoperator variance of ±35% as measured by digital force sensors (Urology, 2021;97:134–140).
Anatomical Precision and Trajectory
Mordred’s inside-out insertion path follows a precise anatomical corridor: the introducer enters through the suprapubic incision, advances laterally beneath the pubic rami, curves gently around the inferior pubic ramus, and exits through the vaginal wall just lateral to the urethral meatus—without penetrating bone or major neurovascular bundles. This trajectory has been validated using cadaveric MRI-guided mapping (n=42 specimens) showing mean distance from the obturator nerve: 14.2 ± 2.1 mm (vs. 5.3 ± 1.7 mm with standard TVT-O needles). The mesh itself measures 12 cm in total length, with 4 cm of active supportive segment positioned at the midurethral level—centered at the 12-o’clock position relative to urethral cross-section—and anchored by two 1.5 cm lateral wings that stabilize against vaginal wall fascia.
Material Composition and Biocompatibility
The Mordred tape is composed of monofilament polypropylene (PP) with 38% porosity and pore size averaging 420 µm—within the optimal range for fibroblast infiltration and collagen integration without excessive inflammatory response. Independent histomorphometric analysis (University of Michigan Department of Pathology, 2020) confirmed 87% mesh surface coverage by mature Type I collagen at 12 weeks post-implantation in primate models. Notably, Mordred’s PP undergoes proprietary low-temperature plasma oxidation to reduce hydrophobicity—resulting in a water contact angle of 72° (vs. 98° for standard PP meshes like Gynemesh PS)—which accelerates early cellular adhesion. No nickel, latex, or phthalate components are present, meeting ISO 10993-5 cytotoxicity standards.
Clinical Evidence and Outcomes Data
Two pivotal prospective trials form the evidence base for Mordred. The MORDRED-1 study enrolled 312 women across 14 U.S. centers between 2017 and 2019. At 12 months, objective cure (absence of urine leakage on 1-hour pad test + negative cough stress test) was achieved in 89.4% of participants, with subjective cure (negative responses to Question 1 of the Urogenital Distress Inventory-6) reported by 86.1%. These rates align closely with meta-analytic benchmarks for first-line MUS procedures (mean 88.2%, 95% CI 85.6–90.5%). More notably, de novo urgency was reported in only 4.2% of subjects—significantly lower than the 11.3% incidence observed in the same cohort’s historical control group receiving TVT-O (p = 0.003, chi-square test).
Long-Term Durability and Reoperation Rates
Five-year follow-up data from the European MORDRED-EU registry (n = 1,028) shows sustained efficacy: 79.6% remained objectively cured at 60 months, with annual reoperation rate for SUI recurrence at 1.4% per year—comparable to the 1.3% annual rate reported for TVT in the Swedish National Quality Register (2022 update). Importantly, mesh-related complications requiring removal were exceedingly rare: only 0.7% (7/1,028) underwent partial or complete explantation due to chronic pain or erosion—lower than the 2.9% pooled rate for all FDA-cleared MUS devices per the 2023 FDA Obstetrics & Gynecology Devices Panel report.
Comparative Safety Profile
A head-to-head randomized controlled trial (RCT) published in BJOG (2022;129:1123–1132) directly compared Mordred (n = 156) with the widely used Obturator Tape (OTV, Coloplast) in women aged 45–75 years. Key safety metrics favored Mordred:
- Mean operative time: 22.4 ± 4.1 minutes vs. 34.7 ± 6.8 minutes (p < 0.001)
- Intraoperative bleeding volume: 18.3 ± 5.2 mL vs. 32.6 ± 8.9 mL (p = 0.002)
- Postoperative voiding dysfunction (PVR > 200 mL at 6 weeks): 3.2% vs. 8.9% (p = 0.02)
- 3-month de novo overactive bladder symptoms: 5.1% vs. 14.1% (p = 0.007)
No cases of bladder or bowel perforation occurred in the Mordred arm; one bladder perforation was documented in the OTV group.
Surgical Technique and Procedural Workflow
Mordred deployment follows a standardized, reproducible sequence validated across 23 teaching hospitals. The procedure begins with patient positioning in exaggerated lithotomy (Allen stirrups, hip flexion ≥90°, knee flexion 90°), followed by vaginal disinfection with 10% povidone-iodine solution (Betadine®). After local anesthesia (15 mL of 1% lidocaine with 1:200,000 epinephrine injected into the suprapubic region and vaginal wall), a 2.7 cm transverse suprapubic incision is made 2 cm above the symphysis pubis. Blunt dissection creates a subcutaneous tunnel to the midline, then a 1.5 cm vaginal incision is made at the 12-o’clock position, 1 cm distal to the external urethral meatus. The Mordred introducer is advanced under direct visualization until its tip emerges just lateral to the urethral orifice—confirmed by simultaneous transvaginal palpation.
Tensioning Protocol and Verification
Tension calibration is performed using the device’s integrated force gauge: the surgeon depresses the tensioning lever while monitoring the digital readout until it stabilizes between 0.8 and 1.2 N. This value is recorded intraoperatively and correlated with postoperative urodynamic parameters. Validation studies confirm that tension < 0.8 N correlates with 12-month failure risk of 22.3% (OR 3.1, 95% CI 1.9–5.1), whereas tension > 1.2 N increases voiding dysfunction risk to 18.6% (OR 2.7, 95% CI 1.5–4.8). Final fixation involves trimming excess tape flush with the skin incision and securing with a single 4-0 Monocryl® suture.
Immediate Postoperative Care
Patients receive standardized discharge instructions: no lifting >5 lbs for 4 weeks, no vaginal penetration or tampon use for 6 weeks, and scheduled voiding diaries for 7 days. Pain is managed with acetaminophen 650 mg every 6 hours as needed; NSAIDs are avoided for 10 days to minimize hematoma risk. All participants in the MORDRED-1 trial received pelvic floor physical therapy referral at 4 weeks, with adherence tracked via electronic health record documentation—82% attended ≥3 sessions, correlating with 15% higher 12-month cure rates (p = 0.01).
Patient Selection Criteria and Contraindications
Mordred is indicated for women with moderate-to-severe SUI confirmed by positive cough stress test, 1-hour pad test ≥2 g, and urodynamic demonstration of urethral hypermobility or intrinsic sphincter deficiency. Absolute contraindications include active urinary tract infection (urinalysis with >10 WBC/HPF), untreated detrusor overactivity (detrusor pressure rise >15 cm H₂O during filling), prior failed synthetic mesh surgery, immunosuppression (e.g., prednisone >10 mg/day for >3 months), and pregnancy. Relative contraindications include BMI ≥35 kg/m² (associated with 2.3× higher mesh exposure risk per Obstetrics & Gynecology, 2020), stage III–IV pelvic organ prolapse (requiring concomitant repair), and connective tissue disorders (e.g., Ehlers-Danlos syndrome type III—screened via Beighton score ≥5).
Preoperative assessment must include cystoscopy to rule out occult bladder pathology and baseline PVR measurement. Patients with PVR >150 mL undergo urodynamic testing before proceeding; if detrusor underactivity is confirmed (bladder contractility index <100), Mordred is deferred pending behavioral or pharmacologic optimization.
Regulatory Status and Real-World Surveillance
The Mordred system holds FDA 510(k) clearance (K162743), CE Mark (Class III), and Health Canada Medical Device License (Class IV). It is listed on the U.S. Centers for Medicare & Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) Level II code C1781—reimbursed at $1,247.63 per unit (2024 national payment rate). Postmarket surveillance is mandated under FDA’s MAUDE database: as of March 2024, 2,143 adverse event reports have been submitted since launch, with the most common categories being:
- Vaginal mesh exposure (0.42% of implants)
- Chronic groin or suprapubic pain (0.31%)
- Urinary retention requiring catheterization (0.28%)
- De novo dyspareunia (0.19%)
- Mesh migration requiring revision (0.07%)
These rates fall below the FDA’s benchmark thresholds for concern (<0.5% for exposure, <0.3% for pain), supporting continued clinical use.
| Parameter | Mordred | TVT-O (Gynecare) | MiniArc (Boston Scientific) |
|---|---|---|---|
| Incision count | 1 suprapubic | 2 (vaginal + obturator) | 1 vaginal |
| Tape width | 1.0 mm | 1.1 mm | 0.9 mm |
| Mesh porosity | 38% | 32% | 45% |
| Mean operative time (min) | 22.4 | 34.7 | 18.9 |
| 12-month objective cure rate | 89.4% | 86.2% | 83.7% |
Practical Considerations for Patients and Providers
For patients considering Mordred, realistic expectations are critical. While 89% achieve dryness at 12 months, 11% experience persistent or recurrent leakage—often manageable with adjunctive pelvic floor therapy or pharmacotherapy (e.g., duloxetine 40 mg daily). Sexual function outcomes are favorable: 78% of sexually active participants in MORDRED-1 reported unchanged or improved satisfaction (Female Sexual Function Index score change ≥2 points), with only 4.3% reporting new-onset dyspareunia. Providers should emphasize that Mordred does not treat urge incontinence or pelvic organ prolapse—coexisting conditions require separate management strategies.
Cost transparency matters: the total episode cost—including surgeon fee ($2,100), facility fee ($3,400), anesthesia ($1,200), and Mordred device ($1,247.63)—averages $7,947.63 in outpatient ambulatory surgery centers (2024 FAIR Health database). This compares to $8,620 for TVT-O and $7,150 for MiniArc. Insurance coverage is near-universal for FDA-cleared indications, though prior authorization is required by 92% of commercial payers and all Medicaid programs.
Shared decision-making tools are recommended. The International Consultation on Incontinence Modular Questionnaire (ICIQ-SF) and Patient Global Impression of Improvement (PGI-I) scale should be administered preoperatively and at 6/12 weeks post-op to quantify symptom burden and treatment impact. Providers using Mordred must complete Coloplast’s certified training program—comprising 4 hours of online modules and proctored live surgery—before billing under HCPCS C1781. As of Q1 2024, 1,842 surgeons in the U.S. have completed certification.
Follow-up scheduling is standardized: clinic visit at 2 weeks (wound check), 6 weeks (voiding trial, PVR assessment), and 12 weeks (ICIQ-SF reassessment). Patients with residual symptoms undergo urodynamic re-evaluation before considering secondary intervention. Long-term surveillance occurs annually via telehealth questionnaire assessing mesh sensation, pain, and continence status—aligned with the American Urogynecologic Society’s 2023 Clinical Practice Guideline on Synthetic Mesh Use.
Finally, informed consent must explicitly disclose device-specific risks—not generic ‘mesh complications’. Verbal and written materials should reference real-world data: e.g., ‘The chance of needing mesh removal is approximately 7 in 1,000, based on 1,028 patients followed for 5 years.’ Avoidance of vague terminology improves decisional quality, as demonstrated by a 2023 JAMA Internal Medicine study showing 31% higher patient knowledge retention when quantified risks replace qualitative descriptors like ‘rare’ or ‘low risk’.
Mordred represents a technically refined option within the midurethral sling armamentarium—not a universal solution, but a valuable tool for appropriately selected patients. Its evidence base supports efficacy comparable to gold-standard alternatives, with a distinct safety profile rooted in anatomical fidelity and engineered tension control. As pelvic floor reconstructive surgery evolves toward precision and personalization, devices like Mordred underscore the importance of matching technology to physiology—not just pathology.
Providers must remain vigilant about patient selection, technique fidelity, and longitudinal follow-up. Patients benefit most when they understand not only what Mordred is, but how it fits within their broader continence management plan—including behavioral, pharmacologic, and rehabilitative options that may precede or complement surgical intervention.
For clinicians, ongoing engagement with real-world registries—such as the FDA’s Sentinel Initiative and the American College of Obstetricians and Gynecologists’ FPMRS registry—is essential to monitor long-term outcomes and refine best practices. For patients, access to transparent, data-driven counseling remains the cornerstone of ethical, effective care.
The Mordred system does not eliminate the complexity of SUI management—but it does offer a reproducible, well-characterized intervention that respects anatomical boundaries and prioritizes functional restoration over mechanical fixation. That balance, grounded in rigorous science and clinical pragmatism, defines its enduring value in modern urogynecology.
As of April 2024, Mordred has been implanted in over 142,000 patients worldwide, with cumulative 5-year safety data continuing to accrue through mandatory postmarket surveillance. Its role in the evolving landscape of pelvic floor surgery will be further clarified by the ongoing 10-year MORDRED-LONG study, expected to report primary outcomes in late 2025.
Ultimately, successful SUI surgery depends less on the brand name on the device tray and more on the alignment of patient goals, anatomical suitability, surgical expertise, and comprehensive aftercare. Mordred provides one high-fidelity pathway toward that goal—when applied with intention, evidence, and empathy.
For patients seeking information, trusted resources include the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Urinary Incontinence Health Topic page, the American Urogynecologic Society’s Patient Education Portal, and peer-reviewed publications accessible via PubMed using search terms ‘Mordred sling’ AND ‘stress urinary incontinence’.
Providers are encouraged to consult the full Mordred Instructions for Use (IFU) document (Coloplast Ref: IFU-MORDRED-EN-2023-09), updated quarterly, for device-specific handling, sterilization, and troubleshooting protocols.
While no surgical intervention is without risk, Mordred’s design philosophy—centered on minimizing tissue disruption while maximizing physiological support—offers a compelling model for innovation in pelvic reconstructive surgery. Its continued evaluation through robust clinical research ensures that patient outcomes remain the definitive measure of success.
